乳腺外科未来的创新方向
该叙述性综述应英国皇家外科医师学会「外科未来委员会」项目要求,围绕降级手术、减少治疗并发症及提高保乳手术切缘准确性等主题征求专家意见。文章指出,术中切缘评估技术可能将保乳术后再切除率减半,前哨淋巴结活检将成为部分淋巴结阳性患者的治疗性手段,肿瘤基因组分析可辅助新辅助与辅助治疗及预防策略的患者选择。
要点
- 术中切缘评估技术可能将保乳术后再切除率减半。
- 前哨淋巴结活检将成为部分淋巴结阳性患者的治疗性手段。
- 肿瘤基因组分析可辅助治疗选择与预防策略。
核心结论
- 治疗正日益基于对肿瘤生物学和相关生物标志物的深入理解进行定制,以确定绝对获益并提供成本效益高的医疗。
- 患者参与对于确保乳腺癌研究的相关性和以患者为中心的客观结局指标至关重要。
研究设计与样本
- 叙述性综述,应英国皇家外科医师学会「外科未来委员会」项目要求撰写,围绕手术降级、减少治疗并发症及提高保乳手术切缘准确性等主题征求专家意见。
主要发现
- 术中切缘评估技术可能将保乳术后再切除率减半。
- 前哨淋巴结活检将成为许多淋巴结阳性患者的治疗性手段,这些患者以手术或化疗作为主要治疗方式。
- 肿瘤基因组分析可辅助选择新辅助和辅助治疗及预防策略的患者。
- 分子亚型可预测对诱导治疗及乳腺或腋窝手术缩减策略的反应。
临床怎么用
- 关注术中切缘评估技术以降低保乳术后再切除率。
- 认识前哨淋巴结活检在部分淋巴结阳性患者中的治疗性角色。
- 利用肿瘤基因组分析和分子亚型指导个体化治疗与手术降级决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Future innovations in science and technology with an impact on multimodal breast cancer management from a surgical perspective are discussed in this narrative review. The work was undertaken in response to the Commission on the Future of Surgery project initiated by the Royal College of Surgeons of England. METHODS: Expert opinion was sought around themes of surgical de-escalation, reduction in treatment morbidities, and improving the accuracy of breast-conserving surgery in terms of margin status. There was emphasis on how the primacy of surgical excision in an era of oncoplastic and reconstructive surgery is increasingly being challenged, with more effective systemic therapies that target residual disease burden, and permit response-adapted approaches to both breast and axillary surgery. RESULTS: Technologies for intraoperative margin assessment can potentially half re-excision rates after breast-conserving surgery, and sentinel lymph node biopsy will become a therapeutic procedure for many patients with node-positive disease treated either with surgery or chemotherapy as the primary modality. Genomic profiling of tumours can aid in the selection of patients for neoadjuvant and adjuvant therapies as well as prevention strategies. Molecular subtypes are predictive of response to induction therapies and reductive approaches to surgery in the breast or axilla. CONCLUSION: Treatments are increasingly being tailored and based on improved understanding of tumour biology and relevant biomarkers to determine absolute benefit and permit delivery of cost-effective healthcare. Patient involvement is crucial for breast cancer studies to ensure relevance and outcome measures that are objective, meaningful, and patient-centred. This article describes how future innovations in science and technology influence the management of breast cancer from a surgical perspective. This work was undertaken in response to the Commission on the Future of Surgery project initiated by the Royal College of Surgeons of England.
引用
- Vidya R, Leff DR, Green M, et al. Innovations for the future of breast surgery. Br J Surg. 2021. PMID: 34059874. doi:10.1093/bjs/znab147
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。